The role of Menin inhibitors in previously untreated, older AML-patients with NPM1 mutations and KMT2A rearrangement is still under investigation in current clinical trials [38] and same applies to triplet combinations like IDH- or FLT3-inhibitors with HMA and venetoclax [39, 40]. Here, NPM1 is linked to acute myeloid leukemia.